1h Free Analyst Time
The pharmacogenomics market is forecasted to grow by USD 2.19 billion during 2023-2028, accelerating at a CAGR of 6.2% during the forecast period. The report on the pharmacogenomics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of genetic diseases and disorders, rising approval of advanced pharmacogenomics testing products, and increasing affordability due to reduction in cost of genetic testing.
The pharmacogenomics market is segmented as below:
By End-user
- Hospitals and clinics
- Research organizations
- Academic
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the pharmacogenomics market covers the following areas:
- Pharmacogenomics Market sizing
- Pharmacogenomics Market forecast
- Pharmacogenomics Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by End-user
9 Customer Landscape
10 Geographic Landscape
11 Drivers, Challenges, and Opportunity/Restraints
12 Competitive Landscape
13 Competitive Analysis
14 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global pharmacogenomics market: 23andMe Holding Co., Abbott Laboratories, Admera Health, ATS GENETECH PVT. LTD., Dynamic DNA Laboratories, geneOmbio Technologies Pvt. Ltd., Illumina Inc., Laboratory Corp. of America Holdings, Mesa Laboratories Inc., Myriad Genetics Inc., OneOme LLC, OPKO Health Inc., QIAGEN N.V., Quest Diagnostics Inc., and Thermo Fisher Scientific Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is growing adoption of direct-to-consumer genetic tests in early disease diagnosis."
According to the report, one of the major drivers for this market is the rising prevalence of genetic diseases and disorders.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 23andMe Holding Co.
- Abbott Laboratories
- Admera Health
- ATS GENETECH PVT. LTD.
- Dynamic DNA Laboratories
- geneOmbio Technologies Pvt. Ltd.
- Illumina Inc.
- Laboratory Corp. of America Holdings
- Mesa Laboratories Inc.
- Myriad Genetics Inc.
- OneOme LLC
- OPKO Health Inc.
- QIAGEN N.V.
- Quest Diagnostics Inc.
- Thermo Fisher Scientific Inc.
